In this review:
Promiscuity
• Nivolumab + cabozantinib
• Cabozantinib + atezolizumab
Provocative: a special combo or just a very fortunate group of patients?
Polish
• SURF’s up
• Do you really need that ipilimumab?
Primaries: what happens with the primary? (#1 & 2)
Prediction: the BIONIKK patient
Possibilities
• ctDNA: not (yet) the biomarker you are looking for
• MK-6482 (HIF2α inhibitor): intriguing potential for VHL-mutated clear-cell
Please login below to download this issue (PDF)